Nano vesicular lipid carriers of angiotensin II receptor blocker: Anti-hypertensive and skin toxicity study in focus

被引:27
|
作者
Ahad, Abdul [1 ]
Aqil, Mohd. [2 ]
Kohli, Kanchan [2 ]
Sultana, Yasmin [2 ]
Mujeeb, Mohd. [2 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia
[2] Jamia Hamdard, Fac Pharm, MB Rd, New Delhi 110062, India
关键词
anti-hypertensive; ethosomes; skin toxicity; valsartan; DRUG-DELIVERY SYSTEMS; VALSARTAN TRANSDERMAL GEL; IN-VITRO EVALUATION; PENETRATION ENHANCERS; PERMEATION; ETHOSOMES; OPTIMIZATION; HYPERTENSION; VESICLES; DESIGN;
D O I
10.3109/21691401.2015.1008509
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: Nanoethosomal carriers of valsartan have been previously prepared, characterized and optimized. A gel formulation of valsartan vesicular lipid carriers was composed of Carbopol((R)) (1% w/w), polyethylene glycol-400 (15% w/w) and triethanolamine (0.5% w/w). The influence of the valsartan nanoethosomal formulation developed on the blood pressure of experimental hypertensive rats, and its potential for skin irritation, are presented in this report. Materials and methods: The experimental rats were divided into three groups; the control group received no treatment (Group A). Group B was administered methyl prednisolone acetate (20 mg/kg/week) for two weeks (hypertensive control). Group C received methyl prednisolone acetate, followed by administration of the valsartan ethosomal formulation. The blood pressure of the rats was measured using a non-invasive rat blood pressure instrument based on the tail-cuff technique. The statistical analysis was performed using GraphPad InStat 3 software. Results and discussion: The treatment group showed a significant (P < 0.05) and constant fall in blood pressure, for up to 48 h. The valsartan ethosomal formulation was found to be effective, with a 34.11% reduction in blood pressure. The formulation's potential for skin irritation was assessed by the Draize irritation score test, which ruled out the possibility of any skin irritation caused by application of the formulation in rats. Conclusion: Our results suggest that nanoethosomes are efficient carriers for transdermal delivery of valsartan, for the management of hypertension.
引用
收藏
页码:1002 / 1007
页数:6
相关论文
共 33 条
  • [21] Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study
    Kunihiko Matsui
    Shokei Kim-Mitsuyama
    Hisao Ogawa
    Tomio Jinnouchi
    Hideaki Jinnouchi
    Kikuo Arakawa
    Hypertension Research, 2014, 37 : 526 - 532
  • [22] Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study
    Matsui, Kunihiko
    Kim-Mitsuyama, Shokei
    Ogawa, Hisao
    Jinnouchi, Tomio
    Jinnouchi, Hideaki
    Arakawa, Kikuo
    HYPERTENSION RESEARCH, 2014, 37 (06) : 526 - 532
  • [23] Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study
    Hisao Mori
    Hareaki Yamamoto
    Hiroshi Ukai
    Shouhei Yuasa
    Kazumi Nakajima
    Takehiko Mikawa
    Masamichi Niizuma
    Kouichi Hirao
    Satoshi Umemura
    Hypertension Research, 2013, 36 : 202 - 207
  • [24] Effects of aliskiren or a diuretic in addition to an angiotensin II receptor blocker on lowering central aortic pressure in non-diabetic hypertensive patients: Results from the ALEA study
    Takahashi, C.
    Miyoshi, T.
    Uesugi, T.
    Sakuragi, S.
    Nanba, S.
    Doi, M.
    Tominaga, Y.
    Murakami, T.
    Oka, T.
    Ito, H.
    EUROPEAN HEART JOURNAL, 2014, 35 : 744 - 744
  • [25] Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study
    Mori, Hisao
    Yamamoto, Hareaki
    Ukai, Hiroshi
    Yuasa, Shouhei
    Nakajima, Kazumi
    Mikawa, Takehiko
    Niizuma, Masamichi
    Hirao, Kouichi
    Umemura, Satoshi
    HYPERTENSION RESEARCH, 2013, 36 (03) : 202 - 207
  • [26] The effect of combination therapy with an L/N-Type Ca2+ channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients:: An observational study conducted in Japan
    Nagahama, Shinobu
    Norimatsu, Takeo
    Maki, Toshio
    Yasuda, Masaharu
    Tanaka, Shinsuke
    HYPERTENSION RESEARCH, 2007, 30 (09) : 815 - 822
  • [27] The Effect of Combination Therapy with an L/N-Type Ca2+ Channel Blocker, Cilnidipine, and an Angiotensin II Receptor Blocker on the Blood Pressure and Heart Rate in Japanese Hypertensive Patients: An Observational Study Conducted in Japan
    Shinobu Nagahama
    Takeo Norimatsu
    Toshio Maki
    Masaharu Yasuda
    Shinsuke Tanaka
    Hypertension Research, 2007, 30 : 815 - 822
  • [28] Rationale, design and method of olmesartan and calcium antagonists randomized (OSCAR) study: The study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients
    Kim-Mitsuyama, S.
    Ogawa, H.
    Jinnouchi, T.
    Arakawa, K.
    JOURNAL OF HYPERTENSION, 2008, 26 : S511 - S511
  • [29] Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: Study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial
    Oh G.C.
    Lee H.-Y.
    Chung W.J.
    Youn H.-J.
    Cho E.-J.
    Sung K.-C.
    Chae S.C.
    Yoo B.-S.
    Park C.G.
    Hong S.J.
    Kim Y.K.
    Hong T.-J.
    Choi D.-J.
    Hyun M.S.
    Ha J.W.
    Kim Y.J.
    Ahn Y.
    Cho M.C.
    Kim S.-G.
    Shin J.
    Park S.
    Sohn I.-S.
    Kim C.-J.
    Clinical Hypertension, 23 (1)
  • [30] Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study
    Yasuhiko Iino
    Matsuhiko Hayashi
    Tetsuya Kawamura
    Tatsuo Shiigai
    Yasuhiko Tomino
    Kenichi Yamada
    Takeyuki Kitajima
    Terukuni Ideura
    Akio Koyama
    Tetsuzo Sugisaki
    Hiromichi Suzuki
    Satoshi Umemura
    Yoshindo Kawaguchi
    Shunya Uchida
    Michio Kuwahara
    Tsutomu Yamazaki
    Journal of Clinical and Experimental Nephrology, 2003, 7 (3): : 221 - 230